Renal Function in Atrial Fibrillation: A Multifaceted Dilemma

Affiliations

¹ From Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Sweden. ziad.hijazi@ucr.uu.se.
² From Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Sweden.

Editorial

Ziad Hijazi et al. Circulation. 2016.

. 2016 Jul 5;134(1):48-51.

doi: 10.1161/CIRCULATIONAHA.116.022994.

¹ From Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Sweden. ziad.hijazi@ucr.uu.se.
² From Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Sweden.

No abstract available

Keywords: Editorials; anti-Xa inhibition; anticoagulation; atrial fibrillation; renal function; vitamin K antagonist.

Comment on

Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E. Bohula EA, et al. Circulation. 2016 Jul 5;134(1):24-36. doi: 10.1161/CIRCULATIONAHA.116.022361. Circulation. 2016. PMID: 27358434 Clinical Trial.
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR; ROCKET AF Steering Committee and Investigators. Fordyce CB, et al. Circulation. 2016 Jul 5;134(1):37-47. doi: 10.1161/CIRCULATIONAHA.116.021890. Circulation. 2016. PMID: 27358435 Clinical Trial.